The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619
Psoralen was confirmed to inhibit proliferation and block the cell cycle in PC3 cells in this <i>in vitro</i> study. The molecular mechanism involves multiple differentially expressed lncRNAs and mRNAs and is related to the down-regulation of lncRNA ENST000000510619 expression. This study provides the experimental basis for the development of psoralen as a novel anti-CRPC drug and for the consideration of lncRNA ENST00000510619 as a potential clinical target for CRPC.
Authors
- Bin Zhan (ORCID: https://orcid.org/0000-0002-6884-9452)
- Mingfang Weng (ORCID: https://orcid.org/0000-0003-1636-4717)
- Rong Ge (ORCID: https://orcid.org/0000-0002-5835-5432)
- Rashid K. Sayyid (ORCID: https://orcid.org/0000-0002-2133-569X)
- Ram A. Pathak (ORCID: https://orcid.org/0000-0003-0578-2649)
- Ronghui Lin (ORCID: https://orcid.org/0000-0001-7951-7253)
- Shushang Chen
- Lingfeng Zhu
- Zhitao Lin (ORCID: https://orcid.org/0000-0002-7312-6021)
- Junjie Wei (ORCID: https://orcid.org/0009-0001-4725-0408)
- Zhenghua Ju
Institutions
- University of Southern California (US)
- Fujian Medical University (CN)
- WinnMed (US)
- Fujian Provincial Hospital (CN)
- Mayo Clinic in Florida (US)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tau-24-457
- Citations
- 1
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.29
Funders
- Natural Science Foundation of Fujian Province